Therapeutic Classification: antirheumatics (DMARDs)
Pharmacologic Classification: fusion proteins
Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism/Excretion: Unknown.
Half-life: 13 days.
(improvement in symptoms)
Neuro: headache, dizziness.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS) , infection (including cytomegalovirus [CMV] and Epstein-Barr virus [EBV] reactivation), MALIGNANCY, infusion-related events.
Rheumatoid Arthritis
- IV (Adults): <60 kg — 500 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter; 60–100 kg — 750 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter; >100 kg — 1000 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter.
- SC (Adults): Treatment may be initiated with or without a single IV dose (according to weight-based dosing guidelines above), then give 125 mg SUBQ within 1 day, then give 125 mg SUBQ once weekly; if patient does not receive IV dose, initiate once weekly SUBQ injections; if transitioning from IV therapy, administer next scheduled dose as SUBQ injection.
Juvenile Idiopathic Arthritis
- IV (Children 6–17 yr and
75 kg): 75–100 kg — 750 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter; >100 kg — 1000 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter. - IV (Children 6–17 yr and <75 kg): 10 mg/kg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter.
- SC (Children 2–17 yr and 50 kg): 125 mg once weekly; initiate treatment without an IV loading dose.
- SC (Children 2–17 yr and 25–<50 kg): 87.5 mg once weekly; initiate treatment without an IV loading dose.
- SC (Children 2–17 yr and 10–<25 kg): 50 mg once weekly; initiate treatment without an IV loading dose.
Psoriatic Arthritis
- IV (Adults): <60 kg — 500 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter; 60–100 kg — 750 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter; >100 kg — 1000 mg initially; repeat dose at 2 wk and 4 wk after initial dose, then every 4 wk thereafter.
- SC (Adults): 125 mg once weekly.
Prophylaxis of Acute Graft Versus Host Disease
- IV (Adults and Children 6 yr): 10 mg/kg (max dose = 1000 mg) on the day before transplantation; repeat dose on Days 5, 14, and 28 after transplantation.
- IV (Children 2–<6 yr): 15 mg/kg on the day before transplantation, then 12 mg/kg on Days 5, 14, and 28 after transplantation.
